Please login to the form below
Loxo Oncology
This page shows the latest Loxo Oncology news and features for those working in and with pharma, biotech and healthcare.
Lilly and Foghorn sign oncology deal
Loxo Oncology, an R&D group within Eli Lilly &Co, is betting that highly selective BRAHMA inhibitors are the key to addressing BRG1 mutated cancers. ... difficult chemistry challenge,” said Jacob Van Naarden, Loxo CEO and president of Lilly Oncology.
Latest news
-
FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
Loxo Oncology at Lilly and president, Lilly Oncology. ... Data supporting this approval will be presented at the European Society for Medical Oncology (ESMO).
-
Lilly restructures in preparation for Alzheimer’s drug launch
Bio-Medicines will actually split in two: Lilly Neuroscience will be overseen by Anne White, who has guided Lilly Oncology for several years, and Lilly Immunology will be led by current ... Jacob (Jake) Van Naarden, currently chief executive officer of
-
Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
Eli Lilly – through its Loxo Oncology R&D development group – has signed an exclusive collaboration agreement with Kumquat Biosciences to develop novel small molecules that stimulate tumour-specific responses. ... chief executive officer of Loxo
-
Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
We are excited to broaden the body of evidence for Retevmo in RET fusion-positive cancers beyond lung and thyroid tumours," said David Hyman, chief medical officer, oncology at Lilly. ... The pharma giant picked up the oral RET inhibitor after acquiring
-
Lilly partners with Merus on development of bispecific antibodies for cancer
Loxo Oncology, which Lilly acquired in 2019, will lend its drug design expertise as part of the agreement, while Merus will leverage its Biclonics platform to research and develop up to ... We expect these therapies will become an important component of
More from news
Approximately 3 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... This is the first US product approval for Loxo Oncology and its
-
Cancer immunotherapy: What's on the horizon?
Following after the first generation of mainly antibody-based immuno-oncology drugs are a host of small-molecule drugs. ... also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due
-
Deal Watch table for July 2013
485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets. ... 208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Origins Insights
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
